PharmaShots’ Key Highlights of Second Quarter 2022

The second quarter of 2022 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Meanwhile, AstraZeneca’s Farxiga (dapagliflozin) meet its primary endpoints for heart failure with a preserved ejection fractionStarting with the latest acquisitions, Pfizer acquire Biohaven for ~$11.6B, GSK acquire Affinivax for ~$3.3B. The second quarter of the year…

BySenior EditorJune 30, 2022

INSIGHTS+

Insights+: COVID-19 Healthcare News Monthly Updates – June 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop itThe outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019.PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where…

BySenior EditorJune 30, 2020

INSIGHTS+

Insights+: COVID-19 Healthcare News Monthly Updates – May 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop itThe outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where…

BySenior EditorMay 29, 2020

PharmaShots’ Key Highlights of Second Quarter 2022

Insights+: COVID-19 Healthcare News Monthly Updates – June 2020

Insights+: COVID-19 Healthcare News Monthly Updates – May 2020

Contact US

OUR INFORMATION

FOLLOW US